Our mission: To achieve the translation of FLASH radiation therapy to clinical use and therefore provide cost-effective treatments to patients as well as improve the radiotherapy patient journey.

Cancer is a leading cause of death in Europe, with the total number of deaths each year estimated at 1.3 million. The economic impact is significant and cancer remains an essential health policy priority. Advances in screening, diagnostics, and treatment have been fundamental to improve survival, but have led to an increase in healthcare spending across Europe, estimated at €103 billion.

The FLASHKNiFE Consortium aims to address this challenge by using FLASH radiation therapy, a recently discovered method of administering radiotherapy. Given in a single, very short treatment session, FLASH radiotherapy has been shown to cause less side effects than conventional radiotherapy in several pre-clinical and clinical studies.